B-MoGen Biotechnologies and CytoSen Therapeutics partner on research collaboration to develop next generation Natural Killer Cells for human therapeutics
MINNEAPOLIS and DALLAS, Jan. 23, 2019 /PRNewswire/ -- B-MoGen Biotechnologies, Inc. and CytoSen Therapeutics announced today a research collaboration to develop the next generation of gene-modified Natural Killer Cell (NK) therapies. B-MoGen will utilize its expertise in genetic design and its patented non-viral gene delivery platform in conjunction with CytoSen's nanoparticle expansion platform to improve efficacy and reduce cost of NK cell therapeutics.
"We are very excited and look forward to teaming up with CytoSen to utilize our scientific expertise and engineering work with CARs and TCRs to help develop NK treatments in the human therapeutics space," said Jeff Liter, President and CEO of B-MoGen. "CytoSen's innovation, science and pioneering technology is a perfect fit with B-MoGen's genome engineering experience and technology."
CytoSen's CEO Dr. Trent Carrier stated, "I am thrilled to see the leveraging of the combined technologies and scientific proficiency of CytoSen and B-MoGen to produce ever more effective NK cell therapeutics. These next generation enhanced NK cells will be put forth in the fight against cancers with the highest unmet medical need."
Both companies are experiencing rapid growth by providing cutting edge science and technical know-how to help create life changing human disease therapies. This partnership looks to enable the creation and delivery of new NK cell therapies for cancer patients.
About B-MoGen Biotechnologies, Inc.
BMoGen Biotechnologies, Inc. is a privately held genome engineering company providing expertise through disruptive, proprietary and cutting-edge gene delivery methods to enable faster research and more cost-effective therapies. B-MoGen partners with scientists and bio-therapeutics companies who create life-changing medicines for human disease. B-MoGen's proprietary and available TcBusterTM technology is a non-viral transposon-based gene therapy platform to support the T-Cell immunotherapy industry that drives down the cost of CAR-T therapy for cancer and other diseases. B-MoGen is demonstrating genome engineering of the mitochondrial genome and is the first company in the world to engineer the mitochondrial genome in human cells with an exclusive license from Mayo Clinic for this technology. B-Mogen is on the cusp of editing and correcting specific mitochondria genetic mutations. B-MoGen also provides fee-for-service custom cell engineering of cell lines for cancer research, drug screening, and antibody validation.
Learn more about B-MoGen at www.Bmogen.com
About CytoSen Therapeutics, Inc.
CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for high dose, cancer-killing NK cells calibrated to each cancer target while reinforcing immune defenses.
Born from the intersection of cellular immunotherapy and nanotechnology, CytoSen's NK cell therapy harnesses the power of the immune system to treat cancer.
Learn more about CytoSen at www.CytoSen.com/
Media and Investors for B-MoGen Biotechnologies, Inc.
Jeff Liter, President & CEO
B-Mogen Biotechnologies, Inc.
Media and Investors for CytoSen Therapeutics, Inc.